

OptiBiotix Health plc
("OptiBiotix" or the "Company" or "the Group")

Large order and Record Early Orders for 2026

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes, announces that it has received four orders totalling twenty-four metric tonnes (24mt) of SlimBiome from Meelung Trading, Taiwan ("Meelung"). These orders will be delivered at approximately three-month intervals throughout 2026 when they will be recorded in the Company's management accounts and reported for the 12 months ended 31 December 2026 ("FY2026").

Meelung started trading in 1949 as a pharmaceutical company before expanding into nutraceuticals in 1992 to exploit the growing market opportunity. It describes itself as one of the most important nutritional supplement distributors in Taiwan with a focus on patented, branded products with clinical studies. OptiBiotix signed an agreement with Meelung in June 2025 and has seen rapid sales growth with regular recurring orders of increasing size.

These orders reflect a growing confidence in SlimBiome and a growing trend with an increasing number of partners placing orders for FY2026 to secure supply. This enables OptiBiotix to plan ahead and consolidate multiple orders, allowing it to negotiate preferential pricing with suppliers and reduce cost. The Company gains flexibility to pass on any cost savings to partners for larger orders while maintaining or improving margins, supporting increased sales growth.

This approach has delivered a record start to FY2026, with over £800K in orders secured from four partners. These will be delivered at various point throughout FY2026 when they will be recorded and reported in the Company's FY2026 accounts. These are confirmed orders with a no cancellation clause and includes the low six figure order received in November 2025 from a well-known weight management company (RNS: 17 November 2025) planned for delivery and launch in H1 2026, the Meelung orders, and two other partners.

These confirmed orders reflect the growing interest in ingredients like SlimBiome which support hunger control and appetite reduction similar to the anti-obesity drugs. This alternative GLP1 market is new and fast evolving and estimated to be worth 1.2 billion in 2024 and projected to reach 4.8 billion by 2033, growing at a compound annual growth rate of 16.7% (Market Intelo, 2024) see [GLP-1 Support Supplements Market Research Report 2033](#). SlimBiome, with its four clinical studies, international awards, and 'on pack health claims' is well positioned to exploit this opportunity.

Stephen O'Hara, CEO of OptiBiotix Health plc said: *"We are pleased to announce this large order from Meelung as well as record orders for the start of 2026. To have already secured orders totalling over £800k before the end of our first month of the year puts us in a strong position for the year ahead. These orders reflect the growing interest in bringing patented, branded ingredients, with human studies demonstrating hunger and appetite reduction to the fast growing 'natural alternative to GLP1' market.*

The Company intends to provide a trading update for the financial year 2025 once figures have been finalised which will show another year of continued strong growth. With the start that we've had so far for 2026, the Company is in the strongest position it has been in with its first-generation products whilst having overcome a number of challenges with partners on large scale production (>100,000 mt) of our second-generation products as we move these along the pathway to launch."

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

Engage with the OptiBiotix management team directly by asking questions, watching video summaries and seeing what other shareholders have to say.

View the full announcement and submit questions to management via our website:

<https://optibiotix.com/link/Pm5WaP>

Subscribe to the new website to get regular updates here: <https://optibiotix.com/auth/signup>

For further information, please contact: OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman
Stephen O'Hara, Chief Executive

Caim Financial Advisers LLP (NOMAD and Broker)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF) OptiBiotix Health has developed a range of technologies and commercialised products which modulate the human microbiome to help prevent and

technologies and commercialised products which modulate the human microbiome to help prevent and manage human disease. Since the Group's inception it has created a wide range of microbiome-based ingredients and products including prebiotic products like SlimBiome®, WellBiome®, SweetBiotix® and Microbiome Modulators within its core OptiBiotix Health plc (OPTI) business, but also skincare through its holdings in SkinBioTherapeutics PLC (SBTX), and probiotics through ProBiotix Health plc (PBX). These companies create a diverse portfolio of technologies and products in an emerging area of healthcare that is of growing interest in consumer markets throughout the world.

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward-looking statements. Forward-looking statements are identified by their use of terms and phrases such as "believe", "could", "should", "envisage", "estimate", "intend", "may", "plan", "potentially", "expect", "will" or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward-looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

CNTURRWRNBUAUAR